Vicapsys
Suwanee · Founded 1997
About Vicapsys
Vicapsys is a biotech company developing treatments for diabetes and other conditions. It focuses on leveraging natural pathways in a localized manner in order to achieve beneficial therapies without systemic negative consequences. At the core of Vicapsys technology is a pleiotropic cytokine, CXCL12 that can be optimally formulated to achieve therapeutic outcomes in different indications. It is currently focused on curing Type 1 diabetes through the long-term survival of transplanted islet cells using a formulation that inhibits the development of the foreign body response and immune protection.
Company Facts
- Founded: 1997
- Legal name: Vicapsys Life Sciences, Inc.
- Operating status: IPO
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $380.0K
- Funding stage: IPO
- Last round: Post-IPO Debt (Jul 2023)
- Website: vicapsys.com
Canonical: https://fsome.com/organization/vicapsys-8276859 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.